Local 12: Pregnancy and addiction
A UC-led study may help reduce complications for babies born to addicted mothers
Researchers at the University of Cincinnati are leading a new trial, aimed at helping babies born to mothers with addiction disorders.
The number of women with opioid use disorder during labor and delivery has risen over the years, according to the National Institute on Drug Abuse. In this pandemic, those who work with this population say it’s gotten even worse.
The coronavirus pandemic has been tough on all expectant moms, but for those struggling with addiction:
“There has been an increase in overdoses with COVID-19,” said Christine Wilder, MD, associate professor and medical director of the Addiction Sciences Division in the Department of Psychiatry and Behavioral Neuroscience at UC and a UC Health physician. “I think more people are anxious. More people are using. It’s harder to get the treatment that you need.”
Watch the full Local 12 report.
Featured photo of Christine Wilder, MD, in clinic by Colleen Kelley.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Local 12: Pregnancy and addiction
March 8, 2021
Local 12 reports on a new study that could give pregnant women with addiction a new tool to deliver a healthy baby. Christine Wilder, MD, is interviewed.
WCPO: Study for opioid addiction treatment during pregnancy
December 4, 2020
UC researchers are seeking participants in a study for an opioid addiction treatment that could weaken withdrawal symptoms and increase the likelihood of recovery for pregnant women.
UC study examines treatment for opioid use disorder
November 17, 2020
A national study being led by UC researchers is investigating whether a medication already used to treat opioid use disorder in women who are pregnant may be more beneficial in an extended-release form.